Free scoping read. A written assessment of your manuscript in two business days, at no cost.

Start one
Contents

Services · Regulatory writing · CTD structure

CTD Structure: The Five Modules and Their Governing Guidelines

The CTD is defined by ICH guideline M4, currently M4(R4). This article explains the four modules common across regions, the regional Module 1 that is not part of the CTD, and the eCTD submission format, which is governed by a separate guideline.

Pubrica AcademyWritten by a research writing specialist Reviewed bya research methodology reviewer Published15 October 2026 Last checked15 October 2026 Reading time12 minutes Sources9 primary

The Common Technical Document is the agreed format for a marketing authorisation application: five modules, four of them common across regions. It is maintained by the International Council for Harmonisation as guideline M4, currently at revision R4.

Overview of the Common Technical Document

M4 “presents the agreed upon common format for the preparation of a well-structured Common Technical Document”1 for applications to regulatory authorities. Before it, the same development programme had to be assembled differently for each region; the CTD made the structure common so that Modules 2 to 5 can be submitted largely unchanged across regions.

The body that maintains it. ICH was the International Conference on Harmonisation until 2015. Its own history records the organisation as “The International Council for Harmonisation (ICH), formerly the International Conference on Harmonisation (ICH)”8, and that “it was reformed and established as a non-profit legal entity under Swiss Law on 23 October 2015.”8 Swissmedic announced the reorganisation at the time9. On a regulatory document the distinction matters, because readers who work with ICH guidelines will notice the outdated name.

The dates. The CTD reached Step 4 of the ICH process on 8 November 2000 — the guideline records “Having reached Step 4 of the ICH Process at the ICH Steering Committee meeting on November 8, 2000”1. The current organisation revision, M4(R4), reached Step 4 on 15 June 2016, “endorsed by the ICH Assembly at Step 4 of the ICH process in June 2016”2. MHRA’s guideline list is the cleanest confirmation that R4 is the current revision7.

A note on national adoption dates

The CTD reached ICH Step 4 on 8 November 2000, agreed between the then-ICH regions of the EU, Japan and the United States. Australia was not one of those parties, so a later national alignment with the CTD format is not the CTD's adoption date.

The Five CTD Modules

Table 1. The CTD modules, and the guideline governing each

ModuleContentsNotesGuideline
Module 1Administrative information and prescribing informationRegion-specific. Labelled “not part of the CTD” in M4’s own diagram.Set by each region, not by M4
Module 2Overviews and summariesThe quality overall summary, the nonclinical overview and summaries, and the clinical overview and summary. This is the module a reviewer reads first.M4(R4) for organisation; M4Q, M4S and M4E for their respective sections
Module 3QualityChemistry, manufacturing and controls.M4Q
Module 4Nonclinical study reportsPharmacology, pharmacokinetics and toxicology.M4S
Module 5Clinical study reportsThe clinical programme, with study reports and listings.M4E

This structure is the purpose of the CTD. Module 1 differs by region, while Modules 2 to 5 do not. Module 2 contains the overviews and summaries that allow a reviewer to understand the programme before reading the study reports, and it is where most of the writing effort goes.

Module 1: Regional Administrative Information Outside the CTD

Many sources state this point less precisely than the guideline does. In M4’s own diagram of the CTD’s organisation, Module 1 carries the annotation “Not part of the CTD”2 — visible on page 6 of the FDA guidance. In the same diagram it is labelled “Regional Administrative Information”, and the guideline’s body text heads it administrative information and prescribing information1.

Why it matters in practice: the content of Module 1 is defined by each region, not by M4. The application form, the proposed labelling, the environmental risk assessment where required, the regional certifications — all of these differ between the FDA, the EMA and the PMDA, and none of them is harmonised. So a dossier is not portable because Module 1 is portable; it is portable because Modules 2 to 5 are, and Module 1 is rebuilt per region.

The ICH M4 Guidelines

M4 is not one document. The organisation guideline sits alongside three content guidelines, one per discipline.

Table 2. The M4 family, current revisions

GuidelineWhat it coversStep 4 date
M4(R4)Organisation of the CTD, including the granularity document15 June 2016
M4Q(R1)Quality — the Module 2.3 quality overall summary and the organisation of Module 3not established; the original M4Q reached Step 4 in November 2000
M4S(R2)Safety — the nonclinical overview and summaries, and the organisation of Module 4not established; the original M4S reached Step 4 in November 2000
M4E(R2)Efficacy — the clinical overview and summary, and the organisation of Module 515 June 2016

Two notes on that table, both about not overstating what is established. M4E(R2) carries its Step 4 date on its face: “This document was endorsed by the ICH Steering Committee at Step 4 of the ICH process on June 15, 2016.”3 The original M4Q and M4S each record a November 2000 Step 4 date4 — “This document was endorsed by the ICH Steering Committee at Step 4 of the ICH process, November 2000.” — but no document we could open states the Step 4 date for the current M4Q(R1) and M4S(R2) revisions. The revisions are current per MHRA’s list7; the dates are simply not stated, so this page does not supply them.

M4E deserves a specific mention because it is the guideline most often omitted. It governs the clinical overview and clinical summary in Module 2 and the organisation of Module 5. Where the clinical programme is central to the submission, leaving this guideline unnamed is a significant gap in any CTD overview3.

Differences Between the CTD and the eCTD

These are routinely conflated, including on pages that set out to explain the CTD. They are different artefacts governed by different guidelines.

Table 3. CTD and eCTD compared

CTDeCTD
What it isA content architecture: what information goes in which module.An electronic submission specification: how the files are built and exchanged.
GuidelineICH M4, currently M4(R4)ICH M8
Live versionsM4(R4)v3.2.2 and v4.0
In ICH’s words“a structural guideline to harmonise the submission file for marketing applications.”“facilitates electronic exchange of regulatory information prepared in accordance with the requirements of the CTD.”
First available8 November 20002003

ICH’s own one-line distinction does the whole job: the eCTD “facilitates electronic exchange of regulatory information prepared in accordance with the requirements of the CTD.”8 — that is, it carries content already structured to the CTD. EMA’s implementation guide for v4.0 describes its scope in the same terms: “It describes the way files should be constructed for inclusion in the eCTD”, and “The goal of upgrading to eCTD v4.0 is to facilitate the processing and review of electronic regulatory submissions.”6

The practical consequence: deciding your dossier’s module structure and deciding your submission format are two separate decisions, taken against two separate guidelines, and a regional requirement to submit in eCTD v4.0 does not change a single thing about what belongs in Module 3.

Current Changes to the CTD

If you are assembling a quality module, M4Q is being revised and the revision is well advanced. ICH’s own working group plan records the sequence5:

Table 4. M4Q(R2) status, from ICH’s working group plan

WhenWhat
May 2025Step 2a. The Assembly endorsed the draft technical document and it was released for public consultation.
November 2025A mock example published.
December 2025The M4Q(R1) to M4Q(R2) mapping published.
March 2026Public consultation closed, with more than 2,500 comments received.
June 2026The working group agreed revisions to sections 2.3.1, 2.3.2, 2.3.3, 2.3.5 and 2.3.6.
November 2026Review and resolution of public comments, anticipated.
March 2027Engagement ahead of Step 3 sign-off, anticipated.
June 2027Step 3 sign-off and Step 4 adoption, anticipated.

Many secondary sources describe the current position incorrectly. Step 2a was reached in May 2025: “Step 2a ICH Assembly endorsed the draft Technical Document and agreed to proceed to the next stage”5 — and the public consultation closed in March 2026. Anything describing the consultation as open is out of date. The working group is resolving comments, with Step 4 adoption projected for June 2027.

Two things published along the way are directly useful now: a mock example in November 2025, and a mapping from M4Q(R1) to M4Q(R2) in December 20255.

Assembling a CTD Submission

How to Apply This Guidance

  1. Write Modules 2 to 5 against M4(R4) for organisation and against M4Q, M4S and M4E for their content — and name M4E explicitly in your document plan, because it is the one most often missed.
  2. Build Module 1 separately for each region you are filing in. It is not part of the CTD and its content is set regionally.
  3. Treat the submission format as a separate decision from the module structure. Check which eCTD version the receiving authority requires.
  4. Write Module 2 as the argument and Modules 3 to 5 as the evidence for it. The overviews are what gets read first and what the review is organised around.
  5. If you are writing a 2.3 quality overall summary or a Module 3 now, read the M4Q(R1)-to-M4Q(R2) mapping, because the revision is at comment resolution and Step 4 is projected for June 2027.
  6. Cite ICH as the International Council for Harmonisation in anything dated after 2015.
  7. Give Step 4 dates for the guideline revision you actually used, and do not attach an original guideline’s date to a later revision.

Take-home message

The CTD is ICH guideline M4, currently M4(R4), and it reached Step 4 on 8 November 2000 with R4 following on 15 June 2016. Four of its five modules are common across regions; Module 1 is labelled “not part of the CTD” in M4’s own diagram and is rebuilt per region. The content guidelines are M4Q, M4S and M4E — and M4E, which governs the clinical module, is the one most often left unnamed. The eCTD is a different guideline, M8: a submission format, not a content architecture. And ICH has been the International Council for Harmonisation since 2015.

Council. ICH was the International Conference on Harmonisation until 2015, when it was reorganised and established as a non-profit legal entity under Swiss law on 23 October of that year, becoming the International Council for Harmonisation. Material still using “Conference” predates that, or has not been updated — and on a regulatory document it is the kind of detail a reviewer notices.

The CTD reached Step 4 of the ICH process on 8 November 2000, agreed between the then-ICH regions: the European Union, Japan and the United States. The current organisation guideline, M4(R4), reached Step 4 on 15 June 2016. Dates on which individual national regulators outside those three regions aligned with the format are later and are not the CTD’s adoption date.

No, and this is more than a technicality. M4’s own organisation diagram labels Module 1 “Not part of the CTD”. It holds administrative and prescribing information whose content each region defines for itself, which is why the same dossier carries a different Module 1 for the FDA, the EMA and the PMDA while Modules 2 to 5 stay common. Describing it as merely “region-specific” understates it.

The CTD is a content architecture — what goes where, in five modules. The eCTD is the electronic submission specification that carries it, and it is a separate ICH guideline, M8. ICH’s own wording is that the eCTD facilitates electronic exchange of regulatory information prepared in accordance with the requirements of the CTD. Two specifications are live, v3.2.2 and v4.0. You can prepare a CTD-structured dossier and submit it in either.

M4E, currently at revision R2, which reached Step 4 on 15 June 2016. It governs the clinical overview and clinical summary in Module 2 as well as the organisation of Module 5. A page describing the CTD that names M4Q and M4S but not M4E leaves the clinical module without a guideline pointer, which is the module most submissions spend the most effort on.

Yes. M4Q(R2) is in development. It reached Step 2a in May 2025 and its public consultation closed in March 2026 with more than 2,500 comments; the working group is resolving those now, with Step 4 adoption projected for June 2027. If you are assembling a Module 3 or a 2.3 quality overall summary, the mapping from M4Q(R1) to M4Q(R2) published in December 2025 is worth reading.

References and Sources

  1. International Council for Harmonisation. ICH Harmonised Tripartite Guideline M4(R4): Organisation of the Common Technical Document for the Registration of Pharmaceuticals for Human Use. Step 4 version, 15 June 2016. read 15 October 2026. View on European Medicines AgencyThe guideline that defines the CTD's five-module organisation. The source for both Step 4 dates: the original CTD on 8 November 2000 and the R4 revision on 15 June 2016.
  2. U.S. Food and Drug Administration. M4 Organization of the Common Technical Document for the Registration of Pharmaceuticals for Human Use: Guidance for Industry. FDA, October 2017. read 15 October 2026. View on U.S. Department of Health and Human ServicesThe FDA copy of ICH M4. Cited specifically because its CTD organisation diagram on page 6 renders the Module 1 annotation in readable text, where the EMA copy does not.
  3. International Council for Harmonisation. M4E(R2): The CTD — Efficacy. Step 4 version, 15 June 2016. FDA Guidance for Industry, July 2017. read 15 October 2026. View on U.S. Department of Health and Human ServicesThe guideline governing Module 5 and the clinical overview and summary. Its absence from a page describing the CTD leaves the clinical module without a guideline pointer.
  4. International Council for Harmonisation. M4Q: The CTD — Quality. Step 4 version, November 2000. FDA Guidance for Industry, August 2001. read 15 October 2026. View on U.S. Department of Health and Human ServicesThe original quality guideline. Cited for its Step 4 date, which is the only M4Q Step 4 date we could confirm; the current R1 revision's date is not stated on any record we could open.
  5. International Council for Harmonisation. M4Q(R2) Expert Working Group Work Plan. ICH, 10 July 2026. read 15 October 2026. View on ICHICH's own work plan for the quality revision. The current status is more advanced than most secondary sources state: the public consultation closed in March 2026 and the working group is resolving comments.
  6. European Medicines Agency. ICH M8: Electronic Common Technical Document (eCTD) v4.0 — draft ICH implementation guide v2.0. EMA/CHMP/ICH/143002/2015 Rev. 1, Step 2. read 15 October 2026. View on European Medicines AgencyThe eCTD is ICH M8, a separate guideline from M4. Two specifications are live, v3.2.2 and v4.0. Conflating the CTD with the eCTD conflates a content architecture with an electronic submission specification.
  7. Medicines and Healthcare products Regulatory Agency. International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use guidelines. MHRA guidance. read 15 October 2026. View on GOV.UKA regulator's current list of ICH guidelines and revisions. Cited for which revision of each M4 guideline is current, which the ICH and EMA documents themselves do not state cleanly.
  8. International Council for Harmonisation. ICH 30th Anniversary Publication. ICH, 2021. read 15 October 2026. View on ICH, via ANVISAICH's own history. The source for the rename from Conference to Council, for the reconstitution as a Swiss non-profit on 23 October 2015, and for the distinction between the CTD as a structural guideline and the eCTD as the electronic exchange format.
  9. Swissmedic. ICH verkündet organisatorische Veränderungen. Swissmedic, 27 October 2015. read 15 October 2026. View on SwissmedicA national regulator's contemporaneous announcement of the reorganisation, which corroborates the rename independently of ICH's own account. The page is in German.

Pubrica AcademyThis article is written and maintained by Pubrica’s regulatory writing specialists. Articles are revised when the underlying standard changes, and each one shows the date it was last checked.

How Pubrica helps

Our regulatory writing team prepares CTD Module 2 overviews and summaries, Module 3 quality sections and Module 5 clinical documentation for sponsors, in line with the current M4 revisions and the receiving authority’s regional Module 1 requirements. If you are assembling a dossier now, we recommend factoring the M4Q revision into your plan.

Get a free quote

Regulations

Check your project against this rule

  1. 1Your work
  2. 2Your details
  3. 3Send
What do you need?

Material you send is held under signed confidentiality, with access limited to the assigned team and encrypted transfer. It is not used to train anything and is not passed to third-party tools. Ask for the agreement before you send anything you would rather cover first.